{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T21:40:03Z","timestamp":1745530803327,"version":"3.40.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.bmcl.2025.130212","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T20:35:27Z","timestamp":1743453327000},"page":"130212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of novel pyridine skeleton derivatives as potent CLK2\/3 inhibitors"],"prefix":"10.1016","volume":"123","author":[{"given":"Jie","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guochuang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bmcl.2025.130212_bb0005","doi-asserted-by":"crossref","first-page":"6047","DOI":"10.3390\/ijms22116047","article-title":"Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and Cdc2-like kinases (CLKs) in human disease, an overview","volume":"22","author":"Lindberg","year":"2021","journal-title":"IJMS"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130212_bb0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41392-023-01409-4","article-title":"Cdc2-like kinases: structure, biological function, and therapeutic targets for diseases","volume":"8","author":"Song","year":"2023","journal-title":"Signal Transduct Tar"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130212_bb0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00412-013-0407-z","article-title":"Regulation of splicing by SR proteins and SR protein-specific kinases","volume":"122","author":"Zhou","year":"2013","journal-title":"Chromosoma"},{"issue":"16","key":"10.1016\/j.bmcl.2025.130212_bb0020","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1074\/jbc.M110.204453","article-title":"Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10","volume":"286","author":"Shi","year":"2011","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130212_bb0025","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/brain\/awq002","article-title":"RNA-targeted splice-correction therapy for neuromuscular disease","volume":"133","author":"Wood","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.bmcl.2025.130212_bb0030","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.joca.2019.05.006","article-title":"Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by Lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment","volume":"27","author":"Deshmukh","year":"2019","journal-title":"Osteoarthr Cartil"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130212_bb0035","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1158\/0008-5472.CAN-14-2443","article-title":"CLK2 is an oncogenic kinase and splicing regulator in breast cancer","volume":"75","author":"Yoshida","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130212_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116952","article-title":"Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer","volume":"280","author":"Hu","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"18","key":"10.1016\/j.bmcl.2025.130212_bb0045","doi-asserted-by":"crossref","first-page":"26793","DOI":"10.18632\/oncotarget.8471","article-title":"Cdc2-like kinase 2 is a key regulator of the cell cycle via FOXO3a\/p27 in glioblastoma","volume":"7","author":"Park","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130212_bb0050","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1742-4690-8-47","article-title":"Differential effect of CLK SR kinases on HIV-1 gene expression: potential novel targets for therapy","volume":"8","author":"Wong","year":"2011","journal-title":"Retrovirology"},{"issue":"21","key":"10.1016\/j.bmcl.2025.130212_bb0055","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1111\/febs.16057","article-title":"Oncogenic dysregulation of pre-mRNA processing by protein kinases: challenges and therapeutic opportunities","volume":"288","author":"Naro","year":"2021","journal-title":"FEBS J"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130212_bb0060","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1742-4658.2010.07992.x","article-title":"Phosphorylation mechanism and structure of serine-arginine protein kinases","volume":"278","author":"Ghosh","year":"2011","journal-title":"FEBS J"},{"issue":"18","key":"10.1016\/j.bmcl.2025.130212_bb0065","doi-asserted-by":"crossref","first-page":"10224","DOI":"10.1021\/acs.jmedchem.0c00898","article-title":"DFG-1 residue controls inhibitor binding mode and affinity providing a basis for rational Design of Kinase Inhibitor Selectivity","volume":"63","author":"Schr\u00f6der","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130212_bb0070","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/6125068","article-title":"Structural basis for the selective inhibition of Cdc2-like kinases by CX-4945","author":"Lee","year":"2019","journal-title":"Biomed Res Int"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130212_bb0075","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.joca.2021.02.004","article-title":"A phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2\/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis","volume":"29","author":"Yazici","year":"2021","journal-title":"Osteoarthr Cartil"},{"key":"10.1016\/j.bmcl.2025.130212_bb0080","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canlet.2019.09.009","article-title":"The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models","volume":"473","author":"Tam","year":"2020","journal-title":"Cancer Lett"},{"issue":"20","key":"10.1016\/j.bmcl.2025.130212_bb0085","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.3390\/ijms21207549","article-title":"Cdc-like kinases (CLKs): biology, chemical probes, and therapeutic potential","volume":"21","author":"Mart\u00edn Moyano","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmcl.2025.130212_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/365192","article-title":"The possible role of Mena protein and its splicing-derived variants in embryogenesis, carcinogenesis, and tumor invasion: a systematic review of the literature","author":"Gurzu","year":"2013","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130212_bb0095","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug resistance in cancer: an overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"issue":"23","key":"10.1016\/j.bmcl.2025.130212_bb0100","doi-asserted-by":"crossref","first-page":"8997","DOI":"10.1021\/jo901641k","article-title":"From imide to lactam metallo-pyridocarbazoles: distinct scaffolds for the design of selective protein kinase inhibitors","volume":"74","author":"Pagano","year":"2009","journal-title":"J Org Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130212_bb0105","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/jor.24898","article-title":"SM04755, a small-molecule inhibitor of the Wnt pathway, as a potential topical treatment for tendinopathy","volume":"39","author":"Deshmukh","year":"2020","journal-title":"J Orthop Res"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25001210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T21:01:56Z","timestamp":1745528516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":21,"alternative-id":["S0960894X25001210"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130212","relation":{},"ISSN":["0960-894X"],"issn-type":[{"type":"print","value":"0960-894X"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel pyridine skeleton derivatives as potent CLK2\/3 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130212"}}